Reshma Kewalramani - Feb 6, 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 6, 2024
Transactions value $
$0
Form type
4
Date filed
2/8/2024, 04:38 PM
Previous filing
Dec 19, 2023
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +14.5K +13.35% $0.00 123K Feb 6, 2024 Direct F1
transaction VRTX Common Stock Award $0 +27K +21.89% $0.00 150K Feb 6, 2024 Direct F2
transaction VRTX Common Stock Award $0 +20.3K +13.53% $0.00 171K Feb 7, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.
F3 Restricted stock unit award that vests in installments beginning on 02/17/2025.